October 6, 2020 04:09 AM EDTUpdated 06:15 AM
Bioregnum
R&D
Opinion

Am­gen posts up­beat as­sess­ment of PhII KRAS da­ta on AMG510 — but there's no clear pic­ture of what re­searchers saw

It’s not un­usu­al to be left want­i­ng af­ter read­ing a top-line press re­lease on close­ly-watched tri­al da­ta. But Am­gen is tak­ing it to a whole …

Endpoints Premium

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE
TRENDING NOW

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

To lead NIH, Trump taps Stan­ford aca­d­e­m­ic and pan­dem­ic re­sponse crit­ic Jay Bhat­tacharya

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

Ad­vanz Phar­ma faces re­vo­ca­tion of Eu­ro­pean au­tho­riza­tion for liv­er dis­ease drug Ocali­va

Bris­tol My­ers sues the fed­er­al gov­ern­ment over 340B, fol­low­ing oth­er drug­mak­ers

A service from the Financial Times